AMEX:VNRX

Volition Achieves CE Mark for Nu.Q® NETs Test

to aid the detection and evaluation of diseases associated with NETosis AUSTIN, Texas, May 31, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® NETs test has been CE marked for the detection and evaluat...

2022-05-31 20:00 2878

VolitionRx Limited Announces First Quarter 2022 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for Thursday, May 12, at 8:30 a.m. U.S. Eastern Time AUSTIN, Texas, May 11, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quar...

2022-05-12 04:10 3143

VolitionRx Limited Schedules First Quarter 2022 Earnings Conference Call and Business Update

Conference call to take place on Thursday May 12 at 08:30 a.m. Eastern Time Capital Markets Day Friday May 13 at 10:00 a.m. Eastern Time AUSTIN, Texas, May 6, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onThursday May 1...

2022-05-06 20:00 3910

VolitionRx Limited to Host Capital Markets Day on Friday May 13

AUSTIN, Texas, May 5, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company plans to host a Capital Markets Day in a hybrid format on  Friday, May 13, 2022, at10 a.m. U.S. Eastern Time.  Volition's executive team will provide strategic upd...

2022-05-05 20:03 1031

Volition Launches its Nu.Q® Vet Cancer Test in Asia Through its Appointed Distributor SAGE Healthcare

AUSTIN, Texas, April 25, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of cancers and other life-altering diseases in both humans and ...

2022-04-25 20:00 2380

Volition appoints Sharon Ballesteros as U.S. Head of Quality and Development Process

AUSTIN, Texas, April 6, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the appointment ofSharon Ballesteros as U.S Head of Quality and Development Process. Sharon has over 20 years of experience within the in vitro d...

2022-04-06 20:00 2547

Volition Signs Exclusive $28 million License and Supply Agreement with Heska Corporation to Distribute Nu.Q® Vet Cancer Screening Test at the Point of Care

AUSTIN, Texas, March 29, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the signing of an exclusive global supply and licensing agreement with Heska Corporation (NASDAQ: HSKA) ("Heska") to sell its Nu.Q® Vet Cancer ...

2022-03-29 20:00 1867

VolitionRx Limited Schedules Full Fiscal Year 2021 Earnings Conference Call and Business Update

Conference call to take place on Thursday March 31 at 08:00a.m. Eastern time AUSTIN, Texas, March 28, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday March 31, 08.00a.m. Eastern time to discuss its financial and ...

2022-03-29 04:25 1803

Volition presents study data at ASCO GI 2022 on circulating nucleosomes for the detection of colorectal cancer and high-risk advanced adenomas

AUSTIN, Texas, Jan. 20, 2022 /PRNewswire/ --VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the results of two large scale clinical studies, which show that the company's Nu.Q® assays, when used in conjunction with the Fecal Immunochemica...

2022-01-20 21:30 3393

Volition Executes its First Supply and Licensing Contract for its Nu.Q® Vet Cancer Screening Test in Asia

* SAGE Healthcare Private Limited appointed to serve as a non-exclusive licensee and distributor for Volition's Nu.Q® Vet Cancer Screening Test in centralized labs inSingapore, with launch planned in Singapore in the first quarter of 2022 followed by expansion in conjunction with SAGE Healthcar...

2021-12-16 21:00 2545

VolitionRx Limited Schedules Third Quarter 2021 Earnings Conference Call and Business Update

AUSTIN, Texas, Nov. 8, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onThursday, November 11, at 8:00 a.m. Eastern time to discuss its financial and operating results for the third quarter of 2021, in addition to providin...

2021-11-08 21:30 2422

Volition Veterinary Presents Two Posters at the 2021 Veterinary Cancer Society Conference

* Positive data show Nu.Q® can be used to monitor for disease response and progression including remission monitoring in cancer bearing dogs. * Paves the way for second Nu.Q® Vet product launch planned for 2022. * A second abstract details the first use of Nu.Q® Capture, Volition's enrichmen...

2021-11-04 20:33 2673

VolitionRx Limited Announces Second Quarter 2021 Financial Results and Business Update

* Strong balance sheet with approximately $27.9 million in cash and cash equivalents * Strengthened the Company's veterinary leadership team to drive commercial focus * Expanded the Company's intellectual property portfolio * Published two clinical papers * Continued focus on, and made s...

2021-08-12 04:10 24585

VolitionRx Limited Schedules Second Quarter 2021 Earnings Conference Call and Business Update

AUSTIN, Texas, Aug. 4, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onThursday, August 12, at 8:00 a.m. Eastern time to discuss its financial and operating results for the second quarter of 2021, in addition to providing...

2021-08-04 20:15 40445

Volition's Nu.Q® NETs Assay Demonstrates Promising Results in COVID-19 Risk Stratification and Disease Monitoring

AUSTIN, Texas, July 22, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has been working w...

2021-07-22 20:00 11318

VolitionRx Limited Announces First Quarter 2021 Financial Results and Business Update

* Secured strongest-ever balance sheet with approximately $33.1 million in cash * Strengthened the Company's leadership team to drive commercial focus * Expanded the Company's intellectual property portfolio * Initiated production of product components at scale at the Company's Silver One ...

2021-05-12 04:10 5582

VolitionRx Limited Schedules First Quarter 2021 Earnings Conference Call and Business Update

AUSTIN, Texas, May 6, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onWednesday May 12, at 8:00 a.m. Eastern time to discuss its financial and operating results for the first quarter of 2021, in addition to providing a bu...

2021-05-06 20:15 3323

VolitionRx Limited Announces Publication of Significant Nu.Q® Capture Mass Spectrometry Paper

AUSTIN, Texas, March 31, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today t...

2021-03-31 20:30 1625

VolitionRx Limited Appoints Dr. Tom Butera DVM as Chief Executive Officer for Volition Veterinary Subsidiary

AUSTIN, Texas, March 30, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today t...

2021-03-30 20:30 2758

VolitionRx Limited Appoints Two New Directors

AUSTIN, Texas, March 29, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today t...

2021-03-30 04:10 3306
12345 ... 7